Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Cipla
Cerilliant
Chinese Patent Office
Julphar
Boehringer Ingelheim
Queensland Health
QuintilesIMS
Fish and Richardson
Daiichi Sankyo

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,233,118

« Back to Dashboard

Which drugs does patent 9,233,118 protect, and when does it expire?


Patent 9,233,118 protects SOOLANTRA and is included in one NDA. There has been one Paragraph IV challenge on Soolantra.

This patent has twenty-six patent family members in thirteen countries.

Summary for Patent: 9,233,118

Title:Treatment of papulopustular rosacea with ivermectin
Abstract: Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments.
Inventor(s): Jacovella; Jean (Antibes, FR), Chappuis; Jean-Paul (Valbonne, FR), Kaoukhov; Alexandre (Newport Beach, CA), Graeber; Michael (Lawrenceville, NJ), Poncet; Michel (Mougins, FR), Briantais; Philippe (Antibes, FR), Salin; Laurence (La Roquette sur Siagne, FR)
Assignee: Galderma S.A. (Cham, CH)
Application Number:14/209,958
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Galderma Labs LpSOOLANTRAivermectinCREAM;TOPICAL206255-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,233,118

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,089,587Treatment of papulopustular rosacea with ivermectin► Subscribe
9,233,117Treatment of inflammatory lesions of rosacea with ivermectin► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,233,118

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Mexico2016000122► Subscribe
Mexico2016000121► Subscribe
South Korea20160061311► Subscribe
South Korea20160061310► Subscribe
Japan2016526572► Subscribe
Japan2016523968► Subscribe
Hong Kong1223842► Subscribe
Hong Kong1223841► Subscribe
European Patent Office3019174► Subscribe
European Patent Office3019173► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Covington
Merck
Chubb
Medtronic
Cantor Fitzgerald
Federal Trade Commission
Chinese Patent Office
US Department of Justice
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot